NCT03769103View on ClinicalTrials.gov

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Lung Cancer Non-small Cell Stage IVBrain Metastases
Interventions
DRUG

Osimertinib

Daily oral osimertinib

RADIATION

Stereotactic radiotherapy

1-5 fractions of stereotactic radiotherapy

Trial Locations (3)

V5Z 4E6

BC Cancer, Vancouver Centre, Vancouver

Unknown

Princess Margaret Hospital, Toronto

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Princess Margaret Hospital, Canada

OTHER

collaborator

Sunnybrook Health Sciences Centre

OTHER

lead

British Columbia Cancer Agency

OTHER